Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1927)	10/24/2007 11:52:50 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

GENR Has been up 31% today, but is up only 14% at present.<g> bigcharts.marketwatch.com It presented some preclinical data of its PI of MSI-1436 at the annual meeting of the NAASO in New Orleans yesterday. The poster presentation entitled, "Trodusquemine is a Protein Tyrosine Phosphatase 1B Inhibitor that Causes Differential Weight Loss",showed that MSI-1436 has selective inhibition of PTP-1B but did not inhibit the activities of DDP-IV, TC-PTP or SHP-2 nor inhibit ligand binding to the CB1 or 5HT2C receptors. Additional in vitro testing demonstrated that MSI-1436 does not activate PPAR (alpha, beta/delta or gamma) nor bind to 250 different kinases. In an animal model, MSI-1436 was found to distribute to both the liver and brain upon peripheral administration and was observed to modify the phosphorylation status of downstream effectors of insulin signaling. The study confirmed that MSI-1436 is a selective inhibitor of PTP-1B, and its central and peripheral effects provide promise for the simultaneous treatment of both type 2 diabetes and obesity. GENR has to deal with the resistance at $2.80 before it can test the more important resistance at the $3.09 level & the spike on Aug 16 at $4.38 <g> bigcharts.marketwatch.com Bernard